COVID-19

This week, we spoke with Mark Lebwohl, M.D., about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.

Gilead announces results from their phase 3 trial investigating different dosing durations for the investigational antiviral drug remdesivir.

Read one New York physician's insights on practice survival and patient care during the pandemic.

David J. Goldberg, M.D., J.D., discusses important considerations regarding telemedicine and HIPAA compliance that dermatologists should keep in mind during the COVID-19 pandemic.

A new symptom is popping up in COVID-19 patients. The virus can reportedly affect not only the lungs, but other internal organs as well as the senses – and now dermatologists are observing skin reactions in patients with the disease.

George Martin, M.D., dermatologist and program director for the Maui Derm meetings, has been working with the Maui Derm faculty, immunologists and members of industry to share emerging data regarding the novel coronavirus with the dermatology community. Listen to his insights in this video.

The coronavirus has created a challenging environment for all dermatology practices. Todd Petersen, CEO of VitalSkin Dermatology, discusses how to make the most of a bad situation by using telemedicine, making plans to reopen and performing a strategic review of your practice. 

In combatting the pandemic, dermatologists must take critical steps to adapt operations while still providing essential patient care and preventing exposure in office settings, experts say.

Jules Lipoff, M.D., dermatologist and assistant professor of clinical dermatology, Penn Medicine, discusses telemedicine in the era of COVID-19.

Governments and the scientific community are racing to identify new and existing drugs that might help flatten the curve and save lives. Read from experts as they discuss the latest news and research surrounding possible treatments for COVID-19.

The American Medical Association announces new resources for private practice physicians during the COVID-19 pandemic.

Experts sent a letter to the White House Coronavirus Task Force March 24, outlining concerns about a growing shortage of medications required for managing patients with lupus and rheumatoid arthritis after President Donald Trump said in a March 19 press conference that the anti-malaria drug hydroxychloroquine could treat COVID-19.

As the number of patients infected with COVID-19 continues to rise, several experts are relaying data they say may save lives and change the course of this pandemic. According to Drs. George Martin, Ted Rosen, Sheila Fallon-Friedlander, Albert Yan, and James Treat, recent data provides evidence of the use of HCQ, its dosing, as well as epidemiology insights that will serve all healthcare practitioners in the fight against the novel coronavirus, COVID-19.

The Journal of Drugs in Dermatology is making additional resources available to medical professionals who wish to continue their education in light of medical conference cancelations due to COVID-19.

The American Academy of Dermatology (AAD) has issued interim recommendations for practitioners to balance the risk of immunosuppression with the risk of disease flare amid COVID-19 pandemic.

The Dermatology Innovation Forum has announced its cancellation amid global spread of the coronavirus.

The American Academy of Dermatology Board of Directors has decided to cancel the 2020 Annual Meeting in Denver due to coronavirus concerns.